Evidence map›Paper›PMID 40684115›Full record

ArticleBMC cancer2025

Imaging features and prognostic significance of immune checkpoint inhibitor-related pneumonitis in NSCLC.

Xueqi Wang, Jingyi Yang, Jiahui E, Fan Liu, Qiliang Wang, Yuwei Zhang, Jing Wang, Ying Liu

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. [Advances in Radiomics for Immune Checkpoint Inhibitor-related Pneumonitis 
of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xueqi WangDepartment of Radiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Jingyi YangDepartment of Radiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Jiahui EDepartment of Radiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Fan LiuDepartment of Radiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Qiliang WangDepartment of Radiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Yuwei ZhangDepartment of Radiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Jing WangDepartment of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Ying LiuDepartment of Radiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China. tjliuying2009@163.com.

Funding

National Natural Science Foundation of China 82472063
6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have demonstrated substantial therapeutic efficacy in the treatment of non-small cell lung cancer (NSCLC); however, their clinical application is associated with unique immune-related adverse effects (irAEs). Among these adverse events, immune checkpoint inhibitor-related pneumonitis (CIP) is rare yet serious, which may potentially result in severe respiratory failure, thereby requiring close clinical monitoring. Research specifically focusing on CIP in NSCLC patients treated with PD-1 inhibitors remain limited. This study targets this distinct cohort to comprehensively investigate the clinical and radiological determinants associated with overall survival, applying time-dependent covariate Cox regression to capture the dynamic impact of prognostic factors over time.

methodsA total of 102 NSCLC participants who received immunotherapy with programmed cell death protein-1 (PD-1) inhibitors and then developed CIP were retrospectively enrolled in this study. Univariate and multivariate time-dependent covariate Cox regression models were constructed to determine associations between CIP features and survival benefits of CIP patients.

resultsThe incidence of CIP was 15% (102/680) with a median onset time of 4.6 months. Fifty-one patients (50.0%) were identified as having organizing pneumonia (OP) pattern, followed by nonspecific interstitial pneumonia (NSIP) pattern in 28 patients (27.4%), hypersensitivity pneumonitis (HP) pattern in 6 patients (5.9%), and diffuse alveolar damage (DAD) pattern in 2 patients (2.0%). Additionally, 15 patients (14.7%) were classified as unclassifiable pattern. Kaplan-Meier analysis and Log-rank test indicated that CIP located around the tumor and with reticular opacity were associated with poorer prognosis (P = 0.023, P = 0.013). Compared to those with CIP grades 2-4, patients with CIP grade 1 demonstrated survival benefit with border-line significance (P = 0.049). Multivariate time-dependent covariate Cox regression analysis showed that CIP improvement or not (χ

conclusionsCIP without improvement or resolution, a high percentage of neutrophils and elevated albumin level of peripheral blood examination were independent predictors for the prognosis of NSCLC patients, which may have an implication for treatment.

Indexed as

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsPneumoniaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTomography, X-Ray ComputedImmune Checkpoint InhibitorsCheckpoint inhibitor-related pneumonitisNon-small cell lung cancerOverall survivalProgrammed cell death protein-1 inhibitors

Identifiers

PMID40684115
PMCPMC12276695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.